Table 3.
The Minimal Clinically Important Difference at each level of baseline severity
| Patient Health Questionnaire -9 |
Generalized Anxiety Disorder Scale -7 |
||||||||
| Baseline Score | Clinical Cut-Off | ED25 | ED50 | ED50 (%) | ED75 | ED25 | ED50 | ED50 (%) | ED75 |
| 1 | Minimal | 0 | 0 | 0 | 1 | 0 | 0 | 0 | N.A. |
| 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | |
| 3 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | |
| 4 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | |
| 5 | Mild | 0 | 0 | 0 | 3 | 0 | 1 | 20 | 4 |
| 6 | 0 | 0 | 0 | 3 | 0 | 2 | 33 | 5 | |
| 7 | 0 | 1 | 14 | 4 | 0 | 2 | 29 | 5 | |
| 8 | 0 | 1 | 13 | 4 | 0 | 3 | 38 | 6 | |
| 9 | 0 | 2 | 22 | 5 | 0 | 4 | 44 | 7 | |
| 10 | Moderate | 0 | 3 | 30 | 5 | 0 | 4 | 40 | 7 |
| 11 | 0 | 3 | 27 | 6 | 0 | 5 | 45 | 8 | |
| 12 | 0 | 4 | 33 | 6 | 1 | 5 | 42 | 8 | |
| 13 | 0 | 4 | 31 | 7 | 2 | 6 | 46 | 9 | |
| 14 | 1 | 5 | 36 | 7 | 2 | 6 | 43 | 9 | |
| 15 | Severe | 1 | 5 | 33 | 8 | 3 | 7 | 47 | 10 |
| 16 | 2 | 5 | 31 | 9 | 3 | 7 | 44 | 11 | |
| 17 | 2 | 6 | 35 | 9 | 4 | 8 | 47 | 11 | |
| 18 | 3 | 7 | 39 | 10 | 5 | 8 | 44 | 12 | |
| 19 | 3 | 7 | 37 | 11 | 5 | 9 | 47 | 12 | |
| 20 | 4 | 8 | 40 | 12 | 6 | 10 | 50 | 13 | |
| 21 | 4 | 9 | 43 | 13 | 6 | 10 | 48 | 13 | |
| 22 | 5 | 10 | 45 | 14 | - | - | - | - | |
| 23 | 6 | 11 | 48 | 14 | - | - | - | - | |
| 24 | 7 | 11 | 46 | 15 | - | - | - | - | |
| 25 | 7 | 12 | 48 | 16 | - | - | - | - | |
| 26 | 8 | 13 | 50 | 17 | - | - | - | - | |
| 27 | 9 | 14 | 52 | 18 | - | - | - | - | |
| Average across sample | 1.2 | 3.7 | 23.3 | 6.4 | 1.0 | 3.3 | 28.0 | 6.1 | |
ED25, effective dose 25; ED50, effective dose 50; ED75, effective dose 75; N.A, not available.